FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032241478> ?p ?o ?g. }

• W2032241478 endingPage "242" @default.
• W2032241478 startingPage "236" @default.
• W2032241478 abstract "Purpose: The aim of this study was to investigate the feasibility and efficacy of personalizing treatment of patients with advanced untreated colorectal cancer (CRC). Patients and Methods: Patients with untreated metastatic CRC, performance status 0-1, and candidates for systemic chemotherapy were eligible. Tumor tissues were analyzed for KRAS , BRAF , and PI3K mutations and expression of topoisomerase-1 (Topo-1), excision repair cross-complementing gene 1 (ERCC1), thymidylate synthase (TS), and thymidine phosphorylase (TP). Patients with Topo-1 expression received irinotecan, whereas patients with negative Topo-1 and ERCC1 expression received oxaliplatin. Otherwise, patients received physician’s choice of treatment. If TS was positive, no fluoropyrimidine was administered and if negative, 5-flurorouracil if TP was negative, or capecitabine if TP was positive. KRAS -mutated patients were treated with bevacizumab, whereas KRAS -native received cetuximab. The primary endpoint of the study was progression-free survival (PFS). Results: A total of 74 patients were enrolled and 67 received personalized treatment including irinotecan (n=27), oxaliplatin (n=16), FOLFIRI (n=12), and FOLFOX (n=12). Thirty-eight patients received cetuximab and 29 bevacizumab. With a median follow-up time of 18.3 months (95% confidence interval [CI], 4-36), the overall median PFS was 8.3 months (95% CI, 6.9-9.7), representing a 12-month PFS rate of 36.5% (95% CI, 25-48). Overall clinical benefit, including response rate and disease stabilization, was 86% (95% CI, 73%-97%). The overall median survival was 21 months (95% CI, 11-40). Conclusions: Real-time target-guided personalized first-line treatment of patients with advanced CRC is feasible but, with the approached used, did not result in a clear improvement in PFS to warrant phase III testing." @default.
• W2032241478 created "2016-06-24" @default.
• W2032241478 creator A5000928175 @default.
• W2032241478 creator A5033798997 @default.
• W2032241478 creator A5044789539 @default.
• W2032241478 creator A5047374807 @default.
• W2032241478 creator A5047923852 @default.
• W2032241478 creator A5048978011 @default.
• W2032241478 creator A5049258935 @default.
• W2032241478 creator A5056339747 @default.
• W2032241478 creator A5063554824 @default.
• W2032241478 creator A5071430061 @default.
• W2032241478 creator A5072151730 @default.
• W2032241478 creator A5086660695 @default.
• W2032241478 creator A5090688944 @default.
• W2032241478 date "2016-06-01" @default.
• W2032241478 modified "2023-10-16" @default.
• W2032241478 title "Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer" @default.
• W2032241478 cites W1653677725 @default.
• W2032241478 cites W1751651908 @default.
• W2032241478 cites W1797303364 @default.
• W2032241478 cites W1980852206 @default.
• W2032241478 cites W2004718750 @default.
• W2032241478 cites W2023240259 @default.
• W2032241478 cites W2026554582 @default.
• W2032241478 cites W2048287147 @default.
• W2032241478 cites W2057623977 @default.
• W2032241478 cites W2100490225 @default.
• W2032241478 cites W2112503651 @default.
• W2032241478 cites W2131348261 @default.
• W2032241478 cites W2133296598 @default.
• W2032241478 cites W2133671458 @default.
• W2032241478 cites W2134519717 @default.
• W2032241478 cites W2135800465 @default.
• W2032241478 cites W2147676721 @default.
• W2032241478 cites W2149428702 @default.
• W2032241478 cites W2152773775 @default.
• W2032241478 cites W2156214772 @default.
• W2032241478 cites W2157978805 @default.
• W2032241478 cites W2161516303 @default.
• W2032241478 cites W2161563098 @default.
• W2032241478 cites W2165963900 @default.
• W2032241478 cites W2166310356 @default.
• W2032241478 cites W4253997817 @default.
• W2032241478 cites W4377200472 @default.
• W2032241478 doi "https://doi.org/10.1097/coc.0000000000000045" @default.
• W2032241478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24517959" @default.
• W2032241478 hasPublicationYear "2016" @default.
• W2032241478 type Work @default.
• W2032241478 sameAs 2032241478 @default.
• W2032241478 citedByCount "4" @default.
• W2032241478 countsByYear W20322414782015 @default.
• W2032241478 countsByYear W20322414782016 @default.
• W2032241478 countsByYear W20322414782017 @default.
• W2032241478 crossrefType "journal-article" @default.
• W2032241478 hasAuthorship W2032241478A5000928175 @default.
• W2032241478 hasAuthorship W2032241478A5033798997 @default.
• W2032241478 hasAuthorship W2032241478A5044789539 @default.
• W2032241478 hasAuthorship W2032241478A5047374807 @default.
• W2032241478 hasAuthorship W2032241478A5047923852 @default.
• W2032241478 hasAuthorship W2032241478A5048978011 @default.
• W2032241478 hasAuthorship W2032241478A5049258935 @default.
• W2032241478 hasAuthorship W2032241478A5056339747 @default.
• W2032241478 hasAuthorship W2032241478A5063554824 @default.
• W2032241478 hasAuthorship W2032241478A5071430061 @default.
• W2032241478 hasAuthorship W2032241478A5072151730 @default.
• W2032241478 hasAuthorship W2032241478A5086660695 @default.
• W2032241478 hasAuthorship W2032241478A5090688944 @default.
• W2032241478 hasConcept C104317684 @default.
• W2032241478 hasConcept C104451858 @default.
• W2032241478 hasConcept C121608353 @default.
• W2032241478 hasConcept C126322002 @default.
• W2032241478 hasConcept C134935766 @default.
• W2032241478 hasConcept C143998085 @default.
• W2032241478 hasConcept C185592680 @default.
• W2032241478 hasConcept C2776694085 @default.
• W2032241478 hasConcept C2776705615 @default.
• W2032241478 hasConcept C2777802072 @default.
• W2032241478 hasConcept C2777909004 @default.
• W2032241478 hasConcept C2778260052 @default.
• W2032241478 hasConcept C2779309665 @default.
• W2032241478 hasConcept C2779998722 @default.
• W2032241478 hasConcept C2780259306 @default.
• W2032241478 hasConcept C2780962732 @default.
• W2032241478 hasConcept C2781187634 @default.
• W2032241478 hasConcept C526805850 @default.
• W2032241478 hasConcept C55493867 @default.
• W2032241478 hasConcept C71924100 @default.
• W2032241478 hasConcept C90924648 @default.
• W2032241478 hasConceptScore W2032241478C104317684 @default.
• W2032241478 hasConceptScore W2032241478C104451858 @default.
• W2032241478 hasConceptScore W2032241478C121608353 @default.
• W2032241478 hasConceptScore W2032241478C126322002 @default.
• W2032241478 hasConceptScore W2032241478C134935766 @default.
• W2032241478 hasConceptScore W2032241478C143998085 @default.
• W2032241478 hasConceptScore W2032241478C185592680 @default.
• W2032241478 hasConceptScore W2032241478C2776694085 @default.
• W2032241478 hasConceptScore W2032241478C2776705615 @default.

• next